ВОЗМОЖНОСТИ СОВРЕМЕННОЙ ХИМИОТЕРАПИИ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ
- Авторы: Романов И.С1
-
Учреждения:
- ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
- Выпуск: № 8 (2014)
- Страницы: 8-12
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/286921
- ID: 286921
Цитировать
Полный текст



Аннотация
Высокодифференцированные формы рака щитовидной железы (ВДРЩЖ) составляют более 90 % случаев. У 10-15 % больных обнаруживаются отдаленные метастазы, что крайне ухудшает прогноз. Терапия радиоактивным йодом остается основной для этой группы больных. Данное лечение обеспечивает хороший результат, но только в том случае, если опухолевые клетки не потеряли способность накапливать радиоактивный йод. Для пациентов с т.н. радиойодрефрактерным ВДРЩЖ прогноз остается весьма неблагоприятным. С крайне обескураживающими результатами применяется стандартная цитотоксическая химиотерапия. За последние годы развитие молекулярной биологии привело к открытию массы мишеней при раке щитовидной железы. Эти мишени включают протоонкогены BRAF и RET, VEGFR и PDGFR, ассоциированные с ангиогенезом, и натрий-йодный симпортер. Наиболее изученными в применении в клинике считаются тирозинкиназные ингибиторы, результаты исследования которых позволили ввести в лечение данной группы пациентов новые таргетные препараты.
Полный текст

Об авторах
И. С Романов
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Email: drromanov@mail.ru
Список литературы
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 году. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010; 21 (2): 160. Прил. 1.
- Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М., 2009.
- O'Neill C.J., Oucharek J., Learoud D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010: 15(2): 146-56.
- Sherman S.I. Thyroid carcinoma. Lancet. 2003; 361: 501-11.
- Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19( 11): 1167-214.
- Perros P., et al. British Thyroid Association Royal College of Physicians; Report of the Thyroid Cancer Guidelines Update Group. Guidelines for the Management of Thyroid Cancer. Second Edition. London: London Royal College of Physicians; 2007. Р. 1-92.
- Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 1994; 97(5): 418-28.
- Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., et al. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2006; 91: 313-19.
- Hoie J., Stenwig A.E., Kullmann G., Lindegaard M. Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer. 1988; 61: 1-6.
- Durante C., Haddy N., Baudin E., Leboulleux S., et al. J. Clin. Endocrinol. Metab. 2006; 91(8): 2892-99.
- Pittas A.G., Adler M., Fazzari M., et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 2000; 10: 261-68.
- Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006; 16(12): 1229-42.
- Casara D., Rubello D., Saladini G., et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J. Nucl. Med. 1993; 34: 1626-31.
- Hodak S.P., Carty S.E. Radioiodineresistant differentiated thyroid cancer: hope for the future. Oncology. 2009; 9: 775-76.
- Gottlieb J.A., Hill C.S. Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N. Engl. J. Med. 1974; 290(4): 193-97.
- Shimaoka K., Schoenfeld D.A., DeWys W.D., et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985; 56: 2155-60.
- Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer. Treat. Rep. 1986; 70: 405-07.
- Sherman S.I. Early clinical studies of novel therapies for thyroid cancers. Endocrinol. Metab. Clin. North. Am. 2008; 37: 511-24.
- Nikiforova M.N., Nikiforov Y.E. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev. Mol. Diagn. 2008; 8: 83-95.
- Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007; 28: 742-62.
- Knauf J.A., Fagin J.A. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr. Opin. Cell. Biol. 2009; 21: 296-303.
- Elisei R., Ugolini C., Viola D., et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J. Clin. Endocrinol. Metab. 2008; 93: 3943-49.
- Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005; 90: 6373-79.
- Riesco-Eizaguirre G., Gutierrez-Martinez P., Garcia-Cabezas M.A., et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer. 2006; 13: 257-69.
- Durante C., Puxeddu E., Ferretti E., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 2007; 92: 2840-43.
- Romei C., Ciampi R., Faviana P., et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr. Relat. Cancer. 2008; 15: 511-20.
- Liu Z., Hou P., Ji M., et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008; 93: 3106-16.
- Santarpia L., El-Naggar A.K., Cote G.J., et al. Phosphatidylinositol 3-kinase/Akt and Ras/Raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2008; 93: 278-84.
- Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 2008; 359: 31-42.
- Pennell N.A., Daniels G.H., Haddad R.I., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008; 18: 317-23.
- Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J. Clin. Oncol. 2008; 26: 4708-13.
- Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 2008; 26: 4714-19.
- Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 2009; 27: 1675-84.
- Hoftijzer H.C., Heemstra K.A., Morreau H., et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 2009; 161(6): 923-31.
- Castellone M.D., Carlomagno F., Salvatore G., et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2008; 22: 1023-38.
- Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer. Res. 2006; 66: 8715-21.
- Castellone M.D., Carlomagno F., Salvatore G., et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin. Endocrinol. Metab. 2008; 22: 1023-38.
- Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318: 287-90.
- Brose M.S., Nutting C.M., Sherman S.I., et al. Rationale and design of DECISION: a doubleblind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011; 11: 349 http://www.biomedcentral.com/1471-2407/11/349
- Brose M.S., Nutting C.M., Jarzab B., et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. Presented at ASCO 2013. J. Clin. Oncol. 2013; 31(suppl): Abstract 4.
- Lopez J.P., Wang-Rodriguez J., Chang C.Y., et al. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope. 2008; 118: 1372-76.
- Lopez J.P., Wang-Rodriguez J., Chang C., et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch. Otolaryngol. Head. Neck. Surg. 2007; 133: 1022-27.
Дополнительные файлы
